Journal
NATURE REVIEWS NEUROLOGY
Volume 13, Issue 12, Pages 711-712Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrneurol.2017.161
Keywords
-
Categories
Funding
- Bayer Schering Pharma
- Biogen Idec
- Novartis
Ask authors/readers for more resources
A compelling need exists for a more reliable risk evaluation of natalizumab-associated progressive multifocal leukoencephalopathy (PML). A new report proposes a refined protocol that uses updated patient-based data and cumulative risk evaluation to provide an improved assessment of the annual risk of PML for patients positive for JC virus.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
